

EnzymaticTherapy®
NATURAL MEDICINES™

January 25, 2003

0909 '03 MAR -3 P1:54

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Haglund, et al showed the effects of Eskimo-3® versus placebo in a clinical trial, which demonstrated superior support for maintaining healthy blood pressure that is already within normal limits.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 

Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/25/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

978 0162

LET 11449

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 13e

EnzymaticTherapy®

NATURAL MEDICINES™

January 23, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Eskimo-3® supplementation has been shown to reduce homocysteine levels.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/23/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 11e

EnzymaticTherapy®

NATURAL MEDICINES™

January 26, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Five separate studies on Eskimo-3® showed support for healthy circulation.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/26/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 14e

EnzymaticTherapy®

NATURAL MEDICINES™

January 27, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Clinical studies show that Eskimo-3® better supports healthy lipoprotein(a) [Lp(a)] levels than highly purified fish oil (HPFO).*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/27/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive

Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 15e

EnzymaticTherapy®

NATURAL MEDICINES™

January 29, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Eskimo-3® provides support for musculoskeletal and joint health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/29/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 17c

EnzymaticTherapy®

NATURAL MEDICINES™

January 30, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Research has demonstrated the efficacy of marine fish oils and their fatty acid constituents in support heart health.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.


By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/30/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,


Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460


www.enzy.com

Eskimo-3 18c

EnzymaticTherapy®
NATURAL MEDICINES™

January 19, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740



RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are examples of omega-3 fatty acids. EPA is a precursor for the formation of prostaglandins that have beneficial effects on the liver, immune and cardiovascular systems.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert C. Doster
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/19/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

Michael P. Devereux

Michael P. Devereux
Chief Financial Officer

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 7c

83357

EnzymaticTherapy®
NATURAL MEDICINES™

January 22, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Eskimo-3® has been shown to significantly increase blood levels of EPA and DHA. Benefits associated with these increases in omega-3 fatty acids include: support for healthy homocysteine levels, retention of healthy cholesterol levels that are already within normal limits, retention of healthy blood pressure, supporting healthy circulation, maintaining healthy lipoprotein levels, and protecting LDL from unfavorable oxidation.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/22/03

825 Challenger Drive
Green Bay, WI 54311-8328

Ph: 920-469-1313

Fax: 888-570-6460

www.enzy.com

Eskimo-3 10e

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,


Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®
NATURAL MEDICINES™

January 20, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	DHA is also important for the development and maintenance of neural structures such as the retina and brain.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/20/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,


Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®

NATURAL MEDICINES™

January 21, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740

RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Saturated straight fatty acids are closely packed together in the cell wall, which becomes stiff, while curved fatty acids such as EPA and DHA take up more space so subsequently the cell walls are more flexible. This flexibility helps support healthy joint function as well as skin and blood vessel elasticity.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: Robert C. Doster
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/21/03

825 Challenger Drive
Green Bay, WI 54311-8328


Ph: 920-469-3333

Fax: 888-570-6460

Eskimo 3.0a

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael P. Devereux". The signature is written in a cursive style with a large, prominent initial "M".

Michael P. Devereux
Chief Financial Officer

EnzymaticTherapy®

NATURAL MEDICINES™

January 24, 2003

Mr. Robert Moore
Office of Nutritional Products, Labeling &
Dietary Supplements, HFS 811
Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740


RE: Label Claims/Disclaimers

Dear Mr. Moore:

This letter is to notify you that Enzymatic Therapy, Inc. at 825 Challenger Drive, Green Bay, Wisconsin 54311 is a distributor and has included statements provided for by section 403(r)(6) of the Food, Drug, and Cosmetic Act on the labels of the following product. These claims are not necessarily for a product we currently market or plan to market in the immediate future, and may be exploratory in nature.

COMPANY	PRODUCT NAME	DIETARY INGREDIENTS	STATEMENTS
Enzymatic Therapy, Inc.	Eskimo-3®	Omega-3 Fatty Acids	Eskimo-3® supplementation has been shown to support healthy blood pressure that is already within normal limits.*

I certify that the information contained in this notice is complete and accurate and that Enzymatic Therapy, Inc. has substantiation that the statements are truthful and not misleading.

By: 
Robert C. Doster

Title: Senior Vice President of Scientific Affairs

Date: 1/24/03

If you have any questions, please contact Robert Doster, Senior Vice President of Scientific Affairs, at (920) 406-3608.

Sincerely,



Michael P. Devereux
Chief Financial Officer